11:13 AM EDT, 06/11/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said Wednesday its drug candidate Telomir-1 "significantly reversed" neurological, hepatic, and kidney symptoms in an animal model of Wilson's disease.

The current in vivo results demonstrated that Telomir-1's copper-regulating properties showed "meaningful" behavioral, physiological, and histological improvements in a genetic animal model of Wilson's disease, the biotechnology company added.

Telomir said the trial showed roughly 50% reduction in copper accumulation in dry liver tissue and up to a 4-to-5-fold reduction in episodic tremor events. The study also improved liver and kidney histopathology.

The company is currently advancing Telomir-1 through investigational new drug-enabled trials and anticipates filing its initial IND by 2025 end, it said, adding that it intends to carry out human clinical trials in H1 next year.

Shares of Telomir were down about 2% in recent Wednesday trading.

Price: 2.01, Change: -0.04, Percent Change: -1.95